Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled preprandial human insulin via AERx iDMS versus subcutaneous insulin aspart in type 2 diabetes
2005-005378-58Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Inhaled human insulin + insulin detemir with Insulin aspart + insulin detemir (2 arms). Primary endpoint: Change in HbA1c from baseline after 52 weeks. Started Apr 2006; status: completed.
02
Drugs
regular human insulininsulin aspartinsulin detemir
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-005378-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005378-58.